WhatsApp Skip to main content

Dr. Harsh J Shah

A systematic review and meta-analysis indicate that neoadjuvant chemotherapy (nCTX) does not offer survival benefits for esophagogastric signet ring cell carcinoma (SRCC) patients. The meta-analysis, which included 3,653 patients from 10 studies, revealed that SRCC patients treated with nCTX followed by surgery have worse survival outcomes compared to those treated with surgery alone. Additionally, SRCC patients exhibit lower histopathological response rates to nCTX compared to non-SRCC patients. These findings highlight the need for further high-quality research to determine the most effective treatment strategies for SRCC. #GastricCancer #NeoadjuvantChemotherapy #OncologyResearch #SurgicalOncology

Rate this post

Leave a Reply

Your email address will not be published. Required fields are marked *

Dr. Harsh J Shah
Dr Harsh Shah - GI & HPB Oncosurgeon in India
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.